MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- GLENMARK PHARMACEUTICALS LIMITED (pharmaceuticals)
- GLENMARK PHARMACEUTICALS LIMITED Financial Data
Glenmark Pharma Fact Sheet (GLPH)
Just Released: The No. 1 Stock to Buy in 2020
Here is the latest financial fact sheet of Glenmark Pharma. For more details, see the Glenmark Pharma quarterly results and Glenmark Pharma share price and chart. For a sector overview, read our pharmaceuticals sector report.
GLENMARK PHARMA Price History
| % ch | % | -0.2 |
| No. of shares | m | 282.17 |
| % ch week | % | 1.2 |
| % ch 1-mth | % | -0.7 |
| % ch 12-mth | % | -46.7 |
| 52 week H/L | Rs | 667.0/267.3 |
GLENMARK PHARMA Financials
| No. of Mths Year Ending |
12 Mar-15* |
12 Mar-16* |
12 Mar-17* |
12 Mar-18* |
12 Mar-19* |
5-Yr Chart Click to enlarge
|
|---|
| GLENMARK PHARMA EQUITY SHARE DATA | |||||||
|---|---|---|---|---|---|---|---|
| High | Rs | 879 | 1,262 | 993 | 930 | 712 | |
| Low | Rs | 752 | 672 | 729 | 517 | 484 | |
| Sales per share (Unadj.) | Rs | 244.4 | 271.1 | 325.5 | 322.6 | 349.6 | |
| Earnings per share (Unadj.) | Rs | 17.5 | 26.3 | 39.3 | 28.5 | 32.8 | |
| Diluted earnings per share | Rs | 16.8 | 26.3 | 39.3 | 28.5 | 32.8 | |
| Cash flow per share (Unadj.) | Rs | 27.1 | 34.6 | 48.7 | 39.2 | 44.3 | |
| Dividends per share (Unadj.) | Rs | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | |
| Adj. dividends per share | Rs | 1.92 | 2.00 | 2.00 | 2.00 | 2.00 | |
| Dividend yield (eoy) | % | 0.2 | 0.2 | 0.2 | 0.3 | 0.3 | |
| Book value per share (Unadj.) | Rs | 86.1 | 128.6 | 159.2 | 183.0 | 198.6 | |
| Adj. book value per share | Rs | 82.8 | 128.6 | 159.2 | 183.0 | 198.6 | |
| Shares outstanding (eoy) | m | 271.29 | 282.16 | 282.17 | 282.17 | 282.17 | |
| Bonus/Rights/Conversions | - | - | ESOP | - | - | ||
| Price / Sales ratio | x | 3.3 | 3.6 | 2.6 | 2.2 | 1.7 | |
| Avg P/E ratio | x | 46.6 | 36.7 | 21.9 | 25.4 | 18.2 | |
| P/CF ratio (eoy) | x | 30.1 | 27.9 | 17.7 | 18.5 | 13.5 | |
| Price / Book Value ratio | x | 9.5 | 7.5 | 5.4 | 4.0 | 3.0 | |
| Dividend payout | % | 11.4 | 7.6 | 5.1 | 7.0 | 6.1 | |
| Avg Mkt Cap | Rs m | 221,284 | 272,778 | 242,991 | 204,206 | 168,625 | |
| No. of employees | `000 | 9.5 | 10.0 | 13.0 | 13.7 | 12.0 | |
| Total wages/salary | Rs m | 12,024 | 13,782 | 16,408 | 18,718 | 20,561 | |
| Avg. sales/employee | Rs Th | 6,961.1 | 7,630.5 | 7,083.9 | 6,636.8 | 8,196.0 | |
| Avg. wages/employee | Rs Th | 1,262.5 | 1,374.8 | 1,265.4 | 1,364.7 | 1,708.1 | |
| Avg. net profit/employee | Rs Th | 499.0 | 741.2 | 855.1 | 586.1 | 768.5 | |
| GLENMARK PHARMA INCOME DATA | |||||||
|---|---|---|---|---|---|---|---|
| Net Sales | Rs m | 66,298 | 76,496 | 91,857 | 91,031 | 98,655 | |
| Other income | Rs m | 219 | 200 | 374 | 914 | 2,081 | |
| Total revenues | Rs m | 66,516 | 76,696 | 92,230 | 91,945 | 100,736 | |
| Gross profit | Rs m | 10,225 | 14,372 | 20,367 | 16,154 | 15,858 | |
| Depreciation | Rs m | 2,600 | 2,343 | 2,644 | 3,019 | 3,259 | |
| Interest | Rs m | 1,902 | 1,789 | 2,373 | 2,856 | 3,346 | |
| Profit before tax | Rs m | 5,943 | 10,440 | 15,724 | 11,193 | 11,335 | |
| Minority Interest | Rs m | 0 | 0 | 0 | 0 | 0 | |
| Prior Period Items | Rs m | 0 | 0 | 0 | 0 | 0 | |
| Extraordinary Inc (Exp) | Rs m | 0 | 0 | -810 | 0 | 1,672 | |
| Tax | Rs m | 1,190 | 3,009 | 3,827 | 3,155 | 3,756 | |
| Profit after tax | Rs m | 4,752 | 7,430 | 11,088 | 8,039 | 9,250 | |
| Gross profit margin | % | 15.4 | 18.8 | 22.2 | 17.7 | 16.1 | |
| Effective tax rate | % | 20.0 | 28.8 | 24.3 | 28.2 | 33.1 | |
| Net profit margin | % | 7.2 | 9.7 | 12.1 | 8.8 | 9.4 | |
| GLENMARK PHARMA BALANCE SHEET DATA | |||||||
|---|---|---|---|---|---|---|---|
| Current assets | Rs m | 53,199 | 59,043 | 68,746 | 69,887 | 66,968 | |
| Current liabilities | Rs m | 37,111 | 39,993 | 27,027 | 32,879 | 40,211 | |
| Net working cap to sales | % | 24.3 | 24.9 | 45.4 | 40.7 | 27.1 | |
| Current ratio | x | 1.4 | 1.5 | 2.5 | 2.1 | 1.7 | |
| Inventory Days | Days | 70 | 75 | 85 | 81 | 83 | |
| Debtors Days | Days | 138 | 119 | 96 | 93 | 81 | |
| Net fixed assets | Rs m | 17,445 | 21,416 | 24,132 | 28,892 | 33,322 | |
| Share capital | Rs m | 271 | 282 | 282 | 282 | 282 | |
| "Free" reserves | Rs m | 23,086 | 36,014 | 44,643 | 51,353 | 55,770 | |
| Net worth | Rs m | 23,357 | 36,296 | 44,925 | 51,635 | 56,052 | |
| Long term debt | Rs m | 25,744 | 24,873 | 45,363 | 41,418 | 35,738 | |
| Total assets | Rs m | 87,429 | 101,929 | 117,639 | 125,954 | 132,888 | |
| Interest coverage | x | 4.1 | 6.8 | 7.6 | 4.9 | 4.4 | |
| Debt to equity ratio | x | 1.1 | 0.7 | 1.0 | 0.8 | 0.6 | |
| Sales to assets ratio | x | 0.8 | 0.8 | 0.8 | 0.7 | 0.7 | |
| Return on assets | % | 7.6 | 9.0 | 11.4 | 8.6 | 9.5 | |
| Return on equity | % | 20.3 | 20.5 | 24.7 | 15.6 | 16.5 | |
| Return on capital | % | 16.0 | 20.0 | 19.1 | 15.1 | 17.8 | |
| Exports to sales | % | 44.8 | 43.2 | 0 | 0 | 0 | |
| Imports to sales | % | 7.1 | 7.4 | 0 | 0 | 0 | |
| Exports (fob) | Rs m | 29,720 | 33,044 | 0 | 0 | 0 | |
| Imports (cif) | Rs m | 4,680 | 5,672 | 0 | 0 | 0 | |
| Fx inflow | Rs m | 31,299 | 36,945 | 56,152 | 36,317 | 62,998 | |
| Fx outflow | Rs m | 10,856 | 61,066 | 8,084 | 9,720 | 22,859 | |
| Net fx | Rs m | 20,443 | -24,122 | 48,068 | 26,598 | 40,140 | |
| GLENMARK PHARMA CASH FLOW | |||||||
|---|---|---|---|---|---|---|---|
| From Operations | Rs m | 4,817 | 3,449 | 6,574 | 16,481 | 13,242 | |
| From Investments | Rs m | -5,400 | -8,802 | -7,124 | -10,133 | -6,990 | |
| From Financial Activity | Rs m | 1,992 | 6,986 | 5,432 | -4,685 | -7,387 | |
| Net Cashflow | Rs m | -311 | 934 | 1,992 | 1,770 | -2,971 | |
Share Holding
|
Company Information
|
|||||||||||||||||||||||||||||||||||||||||
| CHM: Glenn Saldanha (MD) | COMP SEC: Sanjay Kumar Chowdhary | YEAR OF INC: 1977 | BSE CODE: 532296 | FV (Rs): 1 | DIV YIELD (%): 0.6 |
Read: GLENMARK PHARMA 2018-19 Annual Report Analysis
More Pharmaceuticals Company Fact Sheets: ASTRAZENECA PHARMA ALEMBIC LTD SUVEN LIFESCIENCES DISHMAN PHARMA ALEMBIC PHARMA
Compare GLENMARK PHARMA With: ASTRAZENECA PHARMA ALEMBIC LTD SUVEN LIFESCIENCES DISHMAN PHARMA ALEMBIC PHARMA
Compare GLENMARK PHARMA With: ADCOCK INGRAM (S. Africa) MYLAN (US) ACTAVIS (US) TEVA PHARMA (Israel)
|
| |
Today's Market
Sensex Ends 208 Points Lower; Oil & Gas and Metal Stocks Witness Selling(Closing)
India share markets continued to witness selling pressure during closing hours and ended their day on a negative note.
Views on news
GLENMARK PHARMA 2018-19 Annual Report Analysis (Annual Result Update)
Sep 5, 2019 | Updated on Sep 5, 2019Here's an analysis of the annual report of GLENMARK PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of GLENMARK PHARMA. Also includes updates on the valuation of GLENMARK PHARMA.
GLENMARK PHARMA Announces Quarterly Results (1QFY20); Net Profit Down 53.1% (Quarterly Result Update)
Aug 28, 2019 | Updated on Aug 28, 2019For the quarter ended June 2019, GLENMARK PHARMA has posted a net profit of Rs 1 bn (down 53.1% YoY). Sales on the other hand came in at Rs 23 bn (up 7.3% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.
GLENMARK PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 6.6% (Quarterly Result Update)
Jun 3, 2019 | Updated on Jun 3, 2019For the quarter ended March 2019, GLENMARK PHARMA has posted a net profit of Rs 2 bn (up 6.6% YoY). Sales on the other hand came in at Rs 26 bn (up 12.4% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.
GLENMARK PHARMA 2017-18 Annual Report Analysis (Annual Result Update)
Dec 19, 2018 | Updated on Dec 19, 2018Here's an analysis of the annual report of GLENMARK PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of GLENMARK PHARMA. Also includes updates on the valuation of GLENMARK PHARMA.
Aster DM Healthcare (IPO)
Feb 10, 2018Should you subscribe to the IPO of Aster DM Healthcare Ltd?
More Views on NewsMost Popular
My Latest Stock Recommendation (Fast Profits Daily)
Jan 10, 2020The story behind my latest stock recommendation and an important announcement.
Bet on These Smallcap Stocks for Success in 2020 (Profit Hunter)
Jan 14, 2020The smallcap rebound finally seems to here... Make sure you aren't too late to make the most of the biggest wealth making opportunity in a decade.
Your Safe Income Options for 2020 (Fast Profits Daily)
Jan 9, 2020What are you safest investing options in 2020 when interest rates fall.
Guess Which Stocks Are Rising at Double the Speed of Sensex (Profit Hunter)
Jan 15, 2020These stocks can move twice as fast as the Sensex - to take advantage of their money multiplying power get in now as the rally is still just taking shape.. read more to not miss out.
What the Infosys Results Tell Us About the Next Infosys (The 5 Minute Wrapup)
Jan 15, 2020If you're interested in the next Infosys, I'll tell you where to look.
More|
| |
OUR TOP 5 IDEAS
- Free Guide on How to Profit from Sensex 100,000.
- A Simple Test to Find out If a Stock Has 100x Potential
- A Guide to some of the Most Lucrative Stocks in the Market. Download For Free!
- Are You Making One of These 15 Costly Mistakes While Investing. Learn more!
- Revealed: Top 7 Stocks to Consider Buying Right Now...
TRACK GLENMARK PHARMA
- Track your investment in GLENMARK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON GLENMARK PHARMA
GLENMARK PHARMA - JUBILANT LIFE SCIENCES COMPARISON
COMPARE GLENMARK PHARMA WITH
OTHER USEFUL LINKS
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
APPS
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited (Research Analyst) 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.